Torrent semaglutide Brazil launch targeted within nine months but the maker behind it is unnamed

Torrent semaglutide Brazil plans now have a time frame. Torrent Pharmaceuticals told investors it hopes to bring its generic semaglutide to Brazil within six to nine months, after selling the drug only in India so far. The Ahmedabad company gave the timing on its earnings call for the September quarter, when its Brazil sales rose 38 percent. It did not say who will make the Brazilian product, and the report did not say whether the Brazilian regulator has approved it.

What Torrent told investors

Managing Director Aman Mehta gave the timing on the call. "Optimistically, we expect to launch in the next 6-9 months," he said, according to The Hindu BusinessLine. The word optimistically matters: this is a company target, not a filed date, and it depends on review by ANVISA, the Brazilian health regulator. Torrent has 53 products waiting for ANVISA decisions, the paper reported, though it did not say whether semaglutide is one of them or how far that file has moved. Mehta linked the plan to the market itself. He said a large local company's entry into generic semaglutide had sped up growth in Brazil over the past three months, which makes a later arrival a race for share rather than a first move.

Brazil is already a sizeable business for Torrent. Sales there reached 440 crore rupees in the second quarter of the 2027 fiscal year, up 38 percent on a year earlier. In Brazilian currency the gain was 20 percent, to 236 million reais. Torrent said it grew 26 percent in the quarter while the wider market grew 6 percent, citing IQVIA data. For the first half, Brazil sales rose 34 percent to 717 crore rupees. The company runs four units in the country, covering cardiovascular and diabetes, central nervous system drugs, generics and non retail sales. Mehta said he expects Brazil to keep growing in the mid teens. That is a company forecast, and semaglutide would join an existing diabetes unit rather than start a new one.

The Brazil semaglutide market it is entering

Torrent would not be first. The main semaglutide patent in Brazil expired in March 2026. On 26 May 2026 ANVISA approved Ozivy, a semaglutide pen from the Brazilian company EMS, according to a Reuters report. Reuters said the pen would be made at an EMS plant in São Paulo state able to turn out up to 40 million pens a year. It also said ANVISA was then reviewing five other synthetic semaglutide applications and one biological version. That is the local player Mehta described. A domestic maker with its own plant and a large pen line sets the price and volume bar that an importer has to meet.

A domestic maker with its own plant and a large pen line sets the price and volume bar that an importer has to meet.

The detail on synthetic and biological versions matters for how the drug is made. Novo Nordisk grows the backbone of semaglutide in yeast and then finishes it by chemistry, while other makers build the whole chain by chemical synthesis, which is why Reuters counted synthetic and biological files apart. Our explainer on two ways GLP 1 peptides get made sets out the difference. Each route needs its own data package for a regulator. Torrent has not said which route its product uses or where the ingredient comes from. Ingredient quality is also under closer watch in general, after an FDA import alert on two Chinese GLP 1 ingredient plants. None of that has been linked to Torrent, but it shapes how regulators read new files.

Supply lessons from the India launch

The India launch shows why supply is the question to watch. Torrent said its injectable semaglutide was out of the Indian market for nearly two months because of a supply disruption. It brought in a new manufacturing partner and restored supply by September, the paper reported. The company did not name either the old or the new partner, or say which step of production failed. In the Pharmatrac data Mehta cited, Torrent held a 32 percent share of Indian semaglutide sales in the second quarter for oral and injectable forms combined. For tablets, he said Torrent keeps more than 90 percent of sales among generic players, while the injectable gap cost it share that he expects to win back over the coming months.

For Brazil, that history is the clearest guide. A company that relies on an outside maker for its pens carries the risk that one failed partner can stop shipments, as it did in India. Torrent has not said whether the same partner will supply Brazil, whether the product will be made in India and shipped, or whether a Brazilian site is involved. Each option changes how quickly a launch can scale and how exposed it is to a single plant. The company also estimated the first year Indian generic semaglutide market at about 800 crore rupees and said it remains on track for that level. It expects prices per patient to stay broadly stable because it sells semaglutide as a branded business.

What Torrent semaglutide Brazil plans leave open

The Torrent semaglutide Brazil target leaves several facts unknown. The company has not said whether ANVISA has approved its product, which form it will sell first, or how it will price it against EMS and any later entrants. Torrent's Brazil team already sells diabetes medicines, so it has the sales channel. What it has not shown is the supply chain behind the pen. The company's other markets add pressure on the same management team. In Germany, Mehta said, supply problems and price cuts ordered by the government have weighed on the non retail business, and he expects a slight decline before things settle in three to four quarters. That is a further reason to treat the six to nine month window as a target.

For readers tracking where semaglutide is made, the Brazil step fits a wider pattern. Patents have now lapsed in several large markets, and copies are arriving from Indian and Brazilian firms while Chinese makers wait at home. Our earlier story on Chinese makers lining up semaglutide copies shows the same race in another country. Torrent's statement adds a clear Indian entrant to the Brazilian list, but no new capacity has been announced with it. The questions that decide the outcome are practical ones: a regulator decision, a named manufacturer, a launch form, and a price. Until those are public, the plan is a timeline set by the company, not a confirmed launch.

Conclusion

The Torrent semaglutide Brazil plan is a company target of six to nine months, built on a Brazil business that grew 38 percent in the September quarter. It enters a market where EMS already has an approved pen made in São Paulo state. Torrent has not named its manufacturer, its ingredient route or its approval status, and its India supply gap shows why those details matter more than the date.